NCT06387238View on ClinicalTrials.gov

Exploration of the Value of PSMA PET/CT in Dynamic Monitoring of the Efficacy of Novel Endocrine Therapy in Patients With Metastatic Hormone Sensitive Prostate Cancer

NANot yet recruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

May 1, 2025

Study Completion Date

June 30, 2026

Conditions
Prostate Adenocarcinoma
Interventions
DIAGNOSTIC_TEST

PSMA PET/CT

pre-therapeutic PSMA PET/CT and post-therapeutic PSMA PET/CT after three-month novel endocrine therapy.

All Listed Sponsors
lead

Peking University First Hospital

OTHER

NCT06387238 - Exploration of the Value of PSMA PET/CT in Dynamic Monitoring of the Efficacy of Novel Endocrine Therapy in Patients With Metastatic Hormone Sensitive Prostate Cancer | Biotech Hunter | Biotech Hunter